云顶新耀公布国家药品监督管理局批准TrodelvyTM用于治疗转移性乳腺癌的3期药物临床试验申请
November 01, 2020 19:00 ET
|
Everest Medicines
中国上海, Nov. 02, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（Everest Medicines，HKEX 1952.HK），一家专注于创新药开发及商业化的生物制药公司，致力于满足中国（含香港、澳门以及台湾地区）及其它亚洲市场未被满足的医疗需求，今天公布中国国家药品监督管理局通过了TrodelvyTM (sacituzumab...
Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Trodelvy™ for Metastatic Breast Cancer in China
November 01, 2020 19:00 ET
|
Everest Medicines
SHANGHAI, China, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that...
云顶新耀公布在中国开展的Taniborbactam与头孢吡肟联合使用的 1期临床试验主要结果
September 14, 2020 22:00 ET
|
Everest Medicines
中国上海, Sept. 15, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（Everest...
Everest Medicines Announces Top-line Results from Phase 1 Clinical Trial of Taniborbactam in Combination with Cefepime in China
September 14, 2020 22:00 ET
|
Everest Medicines
SHANGHAI, China, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...
云顶新耀宣布治疗IgA肾病药物Nefecon的3期临床试验在中国完成首例患者随机入组
September 07, 2020 22:00 ET
|
Everest Medicines
中国上海, Sept. 08, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（Everest Medicines），一家专注于创新药开发及商业化的生物制药公司，致力于满足中国（含香港、澳门以及台湾地区）及其它亚洲市场未被满足的医疗需求，今天宣布用于治疗IgA肾病（IgAN）的药物Nefecon的全球3期注册研究NefIgArd，已在中国完成首例患者随机入组。 ...
Everest Medicines Announces First Patient Randomized in a Phase 3 Clinical Study of Nefecon for IgA Nephropathy Patients in China
September 07, 2020 22:00 ET
|
Everest Medicines
SHANGHAI, China, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...
云顶新耀宣布用于治疗复杂性腹腔内感染的抗菌药物Xerava™ 首个中国3期临床研究完成患者招募
August 27, 2020 22:00 ET
|
Everest Medicines
中国上海, Aug. 28, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（Everest Medicines）是一家专注于创新药研发及商业化的生物制药公司，致力于满足中国（含香港、澳门以及台湾地区）及其它亚洲市场未被满足的医疗需求，公司宣布本周在中国进行的第一项3期临床研究完成了患者招募工作。这是抗菌药物Xerava™...
Everest Medicines Completes Enrollment of Phase 3 Clinical Trial of Xerava™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections in China
August 27, 2020 22:00 ET
|
Everest Medicines
Top-line data from China Phase 3 trial expected in the fourth quarter of 2020 SHANGHAI, China, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing...
云顶新耀宣布在FGF401联合Pembrolizumab治疗晚期实体瘤的1b/2期临床研究中完成首例受试者给药
August 06, 2020 23:00 ET
|
Everest Medicines
中国上海, Aug. 07, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（Everest Medicines），一家专注于创新药开发及商业化的生物制药公司，致力于满足大中华区及其它亚洲市场未被满足的医疗需求，今日宣布在FGF401联合PD-1抑制剂Pembrolizumab用于治疗晚期实体瘤（例如肝细胞癌）的1b/2期临床研究中完成首例受试者给药。 ...
Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors
August 06, 2020 23:00 ET
|
Everest Medicines
SHANGHAI, China, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...